In this episode our host Dr Sarah Drummond speaks with Dr Thomas Tull about bullous pemphigoid:• The clinical features and risk factors for developing bullous pemphigoid  • How to differentiate bullous pemphigoid from other subepidermal blistering disorders  • Management of bullous pemphigoid including:  o Preferred first and second line agents  o How and when to reduce treatment  o What to do in severe and refractory cases   Resources and further reading: • European guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology, 2022 (updated) (https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.18220) • British Association of Dermatologists’ guidelines for the management of bullous pemphigoid, 2012 (https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.12072)Disclosure: Dr. Tull provides consultancy services for Argenx who market Efgartigimod, which has been referenced in Part 1 and 2 of this series. Recorded date: 26 January 2024Please visit our website https://www.stjohnsdermacademy.com/podcasts for episode notes and references. 

Ver todos los episodios